EUVIMEDEUVIMED entdecken
Open Access

Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia

Sudipta Sen, Paul P Potnuru, Nadia Hernandez, Christina Goehl, Caroline Praestholm, Srikanth Sridhar, Omonele O Nwokolo

JAMA Surgery · 01.06.2024 · 159 (6) · 660

DOI: 10.1001/jamasurg.2024.0111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Surgery, erschienen am 01.06.2024. Verfasst von Sudipta Sen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Critical Care and Pain Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 212-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is rapidly increasing in the US, driven by its expanded approval for weight management in addition to hyperglycemia management in patients with type 2 diabetes. The perioperative safety of these medications, particularly with aspiration risk under anesthesia, is uncertain.

Objective

To assess the association between GLP-1 RA use and prevalence of increased residual gastric content (RGC), a major risk factor for aspiration under anesthesia, using gastric ultrasonography. Design, Setting, and Participants This cross-sectional study prospectively enrolled patients from a large, tertiary, university-affiliated hospital from June 6 through July 12, 2023. Participants followed preprocedural fasting guidelines before an elective procedure under anesthesia. Patients with altered gastric anatomy (eg, from previous gastric surgery), pregnancy, recent trauma (<1 month), or an inability to lie in the right lateral decubitus position for gastric ultrasonography were excluded. Exposure Use of a once-weekly GLP-1 RA. Main Outcomes and Measures The primary outcome was the presence of increased RGC, defined by the presence of solids, thick liquids, or more than 1.5 mL/kg of clear liquids on gastric ultrasonography. Analysis was adjusted for confounders using augmented inverse probability of treatment weighting, a propensity score–based technique. Secondarily, the association between the duration of drug interruption and the prevalence of increased RGC was explored.

Results

Among the 124 participants (median age, 56 years [IQR, 46-65 years]; 75 [60%] female), the prevalence of increased RGC was 56% (35 of 62) in patients with GLP-1 RA use (exposure group) compared with 19% (12 of 62) in patients who were not taking a GLP-1 RA drug (control group). After adjustment for confounding, GLP-1 RA use was associated with a 30.5% (95% CI, 9.9%-51.2%) higher prevalence of increased RGC (adjusted prevalence ratio, 2.48; 95% CI, 1.23-4.97). There was no association between the duration of GLP-1 RA interruption and the prevalence of increased RGC (adjusted odds ratio, 0.86; 95% CI, 0.65-1.14). Conclusions and Relevance Use of a GLP-1 RA was independently associated with increased RGC on preprocedural gastric ultrasonography. The findings suggest that the preprocedural fasting duration suggested by current guidelines may be inadequate in this group of patients at increased risk of aspiration under anesthesia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsHumansFemaleMaleMiddle AgedCross-Sectional StudiesProspective StudiesUltrasonographyAgedGastrointestinal ContentsHypoglycemic AgentsDiabetes Mellitus, Type 2Risk FactorsAnesthesia

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Anesthesiology, Critical Care and Pain Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston.
  • McGovern Medical School, The University of Texas Health Science Center at Houston.

Förderung

  • NIH HHS

Zitieren

APA

Sen, S., Potnuru, P. P., Hernandez, N., Goehl, C., Praestholm, C., Sridhar, S., & Nwokolo, O. O. (2024). Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia. JAMA Surgery, 159(6), 660. https://doi.org/10.1001/jamasurg.2024.0111

Vancouver

Sen S, Potnuru PP, Hernandez N, Goehl C, Praestholm C, Sridhar S, et al. Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia. JAMA Surgery. 2024;159(6):660. doi:10.1001/jamasurg.2024.0111

BibTeX
@article{Sen2024,
  author = {Sen, Sudipta and Potnuru, Paul P and Hernandez, Nadia and Goehl, Christina and Praestholm, Caroline and Sridhar, Srikanth and Nwokolo, Omonele O},
  title = {Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia},
  journal = {JAMA Surgery},
  year = {2024},
  volume = {159},
  number = {6},
  pages = {660},
  doi = {10.1001/jamasurg.2024.0111}
}
Kostenlos starten →